Global Patent Index - EP 2621530 A4

EP 2621530 A4 20140305 - IMPROVED ADJUVANT SYSTEM FOR VACCINE ADMINISTRATION

Title (en)

IMPROVED ADJUVANT SYSTEM FOR VACCINE ADMINISTRATION

Title (de)

VERBESSERTES ADJUVANZIENSYSTEM ZUR VERABREICHUNG VON IMPFSTOFFEN

Title (fr)

SYSTÈME D'ADJUVANT AMÉLIORÉ POUR L'ADMINISTRATION DE VACCINS

Publication

EP 2621530 A4 20140305 (EN)

Application

EP 11831026 A 20110927

Priority

  • US 38734910 P 20100928
  • US 2011001661 W 20110927

Abstract (en)

[origin: WO2012047265A2] The present invention provides adjuvant compositions that have improved stability, increased potency and which provide an enhanced Th,1 response. The present invention also provides methods of making those compositions and administration of the improved adjuvant compositions

IPC 8 full level

A61K 39/39 (2006.01); A61K 31/70 (2006.01); A61K 31/7004 (2006.01); A61K 31/7024 (2006.01); A61K 45/06 (2006.01); A61P 37/00 (2006.01)

CPC (source: EP US)

A61K 31/70 (2013.01 - EP US); A61K 31/7004 (2013.01 - EP US); A61K 31/7024 (2013.01 - EP US); A61K 39/39 (2013.01 - EP US); A61K 45/06 (2013.01 - EP US); A61P 37/00 (2017.12 - EP); A61K 2039/55505 (2013.01 - EP US); A61K 2039/55583 (2013.01 - EP US); Y02A 50/30 (2017.12 - EP)

Citation (search report)

  • [X] WO 2008079464 A2 20080703 - BECTON DICKINSON CO [US], et al
  • [A] BANERJEE KAUSTUV ET AL: "Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.", 20 June 2009, VIROLOGY 20 JUN 2009, VOL. 389, NR. 1-2, PAGE(S) 108 - 121, ISSN: 1096-0341, XP002719138
  • [A] NOLAN T M ET AL: "Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults", VACCINE, ELSEVIER LTD, GB, vol. 26, no. 33, 5 August 2008 (2008-08-05), pages 4160 - 4167, XP022938963, ISSN: 0264-410X, [retrieved on 20080613], DOI: 10.1016/J.VACCINE.2008.05.077
  • [A] ZENG RUIHONG ET AL: "Protective effect of a RSV subunit vaccine candidate G1F/M2 was enhanced by a HSP70-Like protein in mice.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 12 DEC 2008, vol. 377, no. 2, 12 December 2008 (2008-12-12), pages 495 - 499, XP002719139, ISSN: 1090-2104
  • [A] DILLON S B ET AL: "Induction of protective class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant.", VACCINE 1992, vol. 10, no. 5, 1992, pages 309 - 318, XP002719140, ISSN: 0264-410X
  • [A] MARRACK PHILIPPA ET AL: "Towards an understanding of the adjuvant action of aluminium.", NATURE REVIEWS. IMMUNOLOGY APR 2009, vol. 9, no. 4, April 2009 (2009-04-01), pages 287 - 293, XP002719141, ISSN: 1474-1741
  • [A] EXLEY C ET AL: "The immunobiology of aluminium adjuvants: how do they really work?", TRENDS IN IMMUNOLOGY, ELSEVIER LTD. * TRENDS JOURNALS, GB, vol. 31, no. 3, 1 March 2010 (2010-03-01), pages 103 - 109, XP026963575, ISSN: 1471-4906, [retrieved on 20100210]
  • See references of WO 2012047265A2

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2012047265 A2 20120412; WO 2012047265 A3 20120809; EP 2621530 A2 20130807; EP 2621530 A4 20140305; EP 2621530 B1 20160622; US 2013259900 A1 20131003; US 9216215 B2 20151222

DOCDB simple family (application)

US 2011001661 W 20110927; EP 11831026 A 20110927; US 201113261421 A 20110927